{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:47:51Z","timestamp":1793364471756,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T00:00:00Z","timestamp":1723334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T00:00:00Z","timestamp":1723334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1245\/s10434-024-15942-1","type":"journal-article","created":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T19:01:48Z","timestamp":1723402908000},"page":"8585-8595","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Survival Analysis and Recurrence Patterns in 555 Patients with Colorectal Peritoneal Metastases Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy"],"prefix":"10.1245","volume":"31","author":[{"given":"Niccolo","family":"Allievi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sidhom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Vasanth","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexios","family":"Tzivanakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Dayal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Cecil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faheez","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,11]]},"reference":[{"key":"15942_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/srep29765","author":"M Riihimaki","year":"2016","unstructured":"Riihimaki M, Hemminki A, Sundquist J, Hemminki K. Patterns of metastasis in colon and rectal cancer. Sci Rep. 2016. https:\/\/doi.org\/10.1038\/srep29765.","journal-title":"Sci Rep."},{"issue":"12","key":"15942_CR2","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1046\/j.1365-2168.2002.02274.x","volume":"89","author":"DG Jayne","year":"2002","unstructured":"Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89(12):1545\u201350.","journal-title":"Br J Surg."},{"key":"15942_CR3","doi-asserted-by":"publisher","first-page":"9073","DOI":"10.1245\/s10434","volume":"28","author":"C Bakkers","year":"2021","unstructured":"Bakkers C, Lurvink RJ, Rijken A, et al. Treatment strategies and prognosis of patients with synchronous or metachronous colorectal peritoneal metastases: a population-based study. Oncol. 2021;28:9073\u201383. https:\/\/doi.org\/10.1245\/s10434.","journal-title":"Oncol."},{"issue":"8","key":"15942_CR4","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ejso.2013.10.001","volume":"40","author":"YRBM Van Gestel","year":"2014","unstructured":"Van Gestel YRBM, Thomassen I, Lemmens VEPP, et al. Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer. Eur J Surg Oncol. 2014;40(8):963\u20139. https:\/\/doi.org\/10.1016\/j.ejso.2013.10.001.","journal-title":"Eur J Surg Oncol."},{"issue":"12","key":"15942_CR5","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","volume":"17","author":"J Franko","year":"2016","unstructured":"Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database. Lancet Oncol. 2016;17(12):1709\u201319. https:\/\/doi.org\/10.1016\/S1470-2045(16)30500-9.","journal-title":"Lancet Oncol."},{"issue":"2","key":"15942_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/bjs.9281","volume":"101","author":"BJ Moran","year":"2014","unstructured":"Moran BJ, Cecil TD. Treatment of surgically resectable colorectal peritoneal metastases. Br J Surg. 2014;101(2):5\u20137. https:\/\/doi.org\/10.1002\/bjs.9281.","journal-title":"Br J Surg."},{"issue":"20","key":"15942_CR7","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","volume":"21","author":"VJ Verwaal","year":"2003","unstructured":"Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737\u201343. https:\/\/doi.org\/10.1200\/JCO.2003.04.187.","journal-title":"J Clin Oncol."},{"issue":"8","key":"15942_CR8","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/bjc.2014.419","volume":"111","author":"R Mirnezami","year":"2014","unstructured":"Mirnezami R, Mehta AM, Chandrakumaran K, et al. Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone. Br J Cancer. 2014;111(8):1500\u20138. https:\/\/doi.org\/10.1038\/bjc.2014.419.","journal-title":"Br J Cancer."},{"issue":"16","key":"15942_CR9","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1002\/cncr.25116","volume":"116","author":"J Franko","year":"2010","unstructured":"Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116(16):3756\u201362. https:\/\/doi.org\/10.1002\/cncr.25116.","journal-title":"Cancer."},{"issue":"6","key":"15942_CR10","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/SLA.0b013e31827e9289","volume":"257","author":"D Go\u00e9r\u00e9","year":"2013","unstructured":"Go\u00e9r\u00e9 D, Malka D, Tzanis D, et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg. 2013;257(6):1065\u201371. https:\/\/doi.org\/10.1097\/SLA.0b013e31827e9289.","journal-title":"Ann Surg."},{"issue":"2","key":"15942_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(20)30599-4.","journal-title":"Lancet Oncol."},{"issue":"5","key":"15942_CR12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1200\/JCO.2008.19.7160","volume":"27","author":"D Elias","year":"2009","unstructured":"Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27(5):681\u20135. https:\/\/doi.org\/10.1200\/JCO.2008.19.7160.","journal-title":"J Clin Oncol."},{"issue":"7","key":"15942_CR13","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.1245\/s10434-023-13279-9","volume":"30","author":"F Schell","year":"2023","unstructured":"Schell F, Kefleyesus A, Benzerdjeb N, et al. Influence of extraperitoneal metastases on the curative-intent management of colorectal peritoneal metastases. Ann Surg Oncol. 2023;30(7):4444\u201354. https:\/\/doi.org\/10.1245\/s10434-023-13279-9.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"15942_CR14","doi-asserted-by":"publisher","first-page":"4459","DOI":"10.1245\/s10434-023-13463-x","volume":"30","author":"AB Hamed","year":"2023","unstructured":"Hamed AB, Shuai Y, Derby J, et al. Impact of primary tumor location and genomic alterations on survival following cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for colorectal peritoneal metastases. Ann Surg Oncol. 2023;30(7):4459\u201370. https:\/\/doi.org\/10.1245\/s10434-023-13463-x.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"15942_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","volume":"28","author":"D Elias","year":"2010","unstructured":"Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28(1):63\u20138. https:\/\/doi.org\/10.1200\/JCO.2009.23.9285.","journal-title":"J Clin Oncol."},{"issue":"9","key":"15942_CR16","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S1470-2045(20)30322-3","volume":"21","author":"D Go\u00e9r\u00e9","year":"2020","unstructured":"Go\u00e9r\u00e9 D, Glehen O, Quenet F, et al. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP\u2013PRODIGE 15): a randomised, phase 3 study. Lancet Oncol. 2020;21(9):1147\u201354. https:\/\/doi.org\/10.1016\/S1470-2045(20)30322-3.","journal-title":"Lancet Oncol."},{"issue":"16","key":"15942_CR17","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1200\/JCO.2004.10.012","volume":"22","author":"O Glehen","year":"2004","unstructured":"Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284\u201392. https:\/\/doi.org\/10.1200\/JCO.2004.10.012.","journal-title":"J Clin Oncol."},{"issue":"8","key":"15942_CR18","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1093\/jnci\/djab001","volume":"113","author":"E Breuer","year":"2021","unstructured":"Breuer E, Hebeisen M, Schneider MA, et al. Site of recurrence and survival after surgery for colorectal peritoneal metastasis. J Natl Cancer Inst. 2021;113(8):1027\u201335. https:\/\/doi.org\/10.1093\/jnci\/djab001.","journal-title":"J Natl Cancer Inst."},{"issue":"8","key":"15942_CR19","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/jso.23597","volume":"109","author":"HJ Braam","year":"2014","unstructured":"Braam HJ, Van Oudheusden TR, De Hingh IHJT, et al. Patterns of recurrence following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. J Surg Oncol. 2014;109(8):841\u20137. https:\/\/doi.org\/10.1002\/jso.23597.","journal-title":"J Surg Oncol."},{"issue":"1","key":"15942_CR20","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1245\/s10434-023-14443-x","volume":"31","author":"CG Tran","year":"2024","unstructured":"Tran CG, Goffredo P, Mott SL, et al. Conditional overall survival after diagnosis of non-metastatic colon cancer: impact of laterality, MSI, and KRAS status. Ann Surg Oncol. 2024;31(1):142\u201351. https:\/\/doi.org\/10.1245\/s10434-023-14443-x.","journal-title":"Ann Surg Oncol."},{"key":"15942_CR21","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/SLA.0b013e3182a5025a","volume":"258","author":"JN Vauthey","year":"2013","unstructured":"Vauthey JN, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258:619\u201326. https:\/\/doi.org\/10.1097\/SLA.0b013e3182a5025a.","journal-title":"Ann Surg."},{"issue":"10","key":"15942_CR22","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1007\/s11605-018-3978-4","volume":"23","author":"P Goffredo","year":"2019","unstructured":"Goffredo P, Utria AF, Beck AC, et al. The prognostic impact of KRAS mutation in patients having curative resection of synchronous colorectal liver metastases. J Gastrointest Surg. 2019;23(10):1957\u201363. https:\/\/doi.org\/10.1007\/s11605-018-3978-4.","journal-title":"J Gastrointest Surg."},{"issue":"5","key":"15942_CR23","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1097\/SLA.0000000000002899","volume":"268","author":"MA Schneider","year":"2018","unstructured":"Schneider MA, Eden J, Pache B, et al. Mutations of RAS\/RAF proto-oncogenes impair survival after cytoreductive surgery and HIPEC for peritoneal metastasis of colorectal origin. Ann Surg. 2018;268(5):845\u201353. https:\/\/doi.org\/10.1097\/SLA.0000000000002899.","journal-title":"Ann Surg."},{"key":"15942_CR24","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker P. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359\u201374.","journal-title":"Cancer Treat Res."},{"issue":"2","key":"15942_CR25","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/00000658-199502000-00002","volume":"221","author":"PH Sugarbaker","year":"1995","unstructured":"Sugarbaker PH, Jablonski KA. Prognostic features of 51 Colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221(2):124\u201332.","journal-title":"Ann Surg."},{"issue":"3","key":"15942_CR26","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1245\/s10434-023-14608-8","volume":"31","author":"E Sarfaty","year":"2024","unstructured":"Sarfaty E, Khajoueinejad N, Yu AT, et al. Actual 5-year survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2024;31(3):1970\u20139. https:\/\/doi.org\/10.1245\/s10434-023-14608-8.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"15942_CR27","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/jso.27370","volume":"128","author":"S Ghabra","year":"2023","unstructured":"Ghabra S, Chang D, Sugarbaker PH. Prognostic indicators for colorectal peritoneal metastases are different for patients with complete versus incomplete cytoreductive surgery. J Surg Oncol. 2023;128(5):860\u20138. https:\/\/doi.org\/10.1002\/jso.27370.","journal-title":"J Surg Oncol."},{"issue":"9","key":"15942_CR28","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","volume":"15","author":"VJ Verwaal","year":"2008","unstructured":"Verwaal VJ, Bruin S, Boot H, Van Slooten G, Van Tinteren H. 8-Year follow-up of randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426\u201332. https:\/\/doi.org\/10.1245\/s10434-008-9966-2.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"15942_CR29","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.jamcollsurg.2006.08.024","volume":"203","author":"RG da Silva","year":"2006","unstructured":"da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. 2006;203(6):878\u201386. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2006.08.024.","journal-title":"J Am Coll Surg."},{"issue":"9","key":"15942_CR30","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s10151-017-1679-8","volume":"21","author":"BJ Moran","year":"2017","unstructured":"Moran BJ. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: from novelty to routine in selected cases. Tech Coloproctol. 2017;21(9):767\u20139. https:\/\/doi.org\/10.1007\/s10151-017-1679-8.","journal-title":"Tech Coloproctol."},{"key":"15942_CR31","unstructured":"NHS Commissioning Board. Clinical commissioning policy: cytoreductive surgery for peritoneal carcinomatosis. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2018\/07\/Cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-for-peritoneal-mesothelioma.pdf."},{"issue":"5","key":"15942_CR32","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/s41416-021-01620-6","volume":"126","author":"SG Larsen","year":"2022","unstructured":"Larsen SG, Goscinski MA, Dueland S, et al. Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients. Br J Cancer. 2022;126(5):726\u201335. https:\/\/doi.org\/10.1038\/s41416-021-01620-6.","journal-title":"Br J Cancer."},{"issue":"7","key":"15942_CR33","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.ejso.2022.02.001","volume":"48","author":"PH Sugarbaker","year":"2022","unstructured":"Sugarbaker PH, Chang D. Peritoneal metastases from colorectal cancer in the absence of lymph node metastases show a high survival rate despite unfavorable prognostic indicators. Eur J Surg Oncol. 2022;48(7):1619\u201325. https:\/\/doi.org\/10.1016\/j.ejso.2022.02.001.","journal-title":"Eur J Surg Oncol."},{"issue":"14","key":"15942_CR34","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1158\/0008-5472.CAN-10-0192","volume":"70","author":"M Janakiraman","year":"2010","unstructured":"Janakiraman M, Vakiani E, Zeng Z, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res. 2010;70(14):5901\u201311. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-0192.","journal-title":"Cancer Res."},{"issue":"24","key":"15942_CR35","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1002\/cncr.28954","volume":"120","author":"NE Kemeny","year":"2014","unstructured":"Kemeny NE, Chou JF, Capanu M, et al. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer. 2014;120(24):3965\u201371. https:\/\/doi.org\/10.1002\/cncr.28954.","journal-title":"Cancer."},{"issue":"6","key":"15942_CR36","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1001\/jamaoncol.2015.0569","volume":"6","author":"MD Lipsyc","year":"2015","unstructured":"Lipsyc MD, Yaeger R. Impact of somatic mutations on patterns of metastasis in colorectal cancer. J Gastrointest Oncol. 2015;6(6):645\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2015.0569.","journal-title":"J Gastrointest Oncol."},{"issue":"8","key":"15942_CR37","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1245\/s10434-019-07378-9","volume":"26","author":"A Arjona-Sanchez","year":"2019","unstructured":"Arjona-Sanchez A, Rodriguez-Ortiz L, Baratti D, et al. RAS mutation decreases overall survival after optimal cytoreductive surgery and hyperthermic intraperitoneal chemotherapy of colorectal peritoneal metastasis: a modification proposal of the peritoneal surface disease severity score. Ann Surg Oncol. 2019;26(8):2595\u2013604. https:\/\/doi.org\/10.1245\/s10434-019-07378-9.","journal-title":"Ann Surg Oncol."},{"issue":"15","key":"15942_CR38","doi-asserted-by":"publisher","first-page":"e16052","DOI":"10.1200\/JCO.2020.38.15_suppl.e16052","volume":"38","author":"J Uhlig","year":"2020","unstructured":"Uhlig J, Cecchini M, Stein S, Lacy J, Kim K. Microsatellite instability and KRAS mutation in stage 4 CRC: prevalence, geographic discrepancies and outcomes from the National Cancer Database. J Clin Oncol. 2020;38(15):e16052.","journal-title":"J Clin Oncol."},{"issue":"20","key":"15942_CR39","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","volume":"20","author":"S Venderbosch","year":"2014","unstructured":"Venderbosch S, Nagtegaal ID, Maughan TS, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014;20(20):5322\u201330. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0332.","journal-title":"Clin Cancer Res."},{"issue":"13","key":"15942_CR40","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1245\/s10434-020-08733-x","volume":"27","author":"SK Sherman","year":"2020","unstructured":"Sherman SK, Schuitevoerder D, Chan CHF, Turaga KK. Metastatic colorectal cancers with mismatch repair deficiency result in worse survival regardless of peritoneal metastases. Ann Surg Oncol. 2020;27(13):5074\u201383. https:\/\/doi.org\/10.1245\/s10434-020-08733-x.","journal-title":"Ann Surg Oncol."},{"issue":"9","key":"15942_CR41","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182\u201391. https:\/\/doi.org\/10.1016\/S1470-2045(17)30422-9.","journal-title":"Lancet Oncol."},{"issue":"16","key":"15942_CR42","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1200\/JCO.2022.40.16_suppl.3511","volume":"40","author":"YL Verschoor","year":"2022","unstructured":"Verschoor YL, Van Den Berg JE, Beets G, et al. Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: final clinical analysis of the NICHE study. J Clin Oncol. 2022;40(16):3511\u20133511.","journal-title":"J Clin Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15942-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-15942-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15942-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T13:03:32Z","timestamp":1731071012000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-15942-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,11]]},"references-count":42,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["15942"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-15942-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,11]]},"assertion":[{"value":"30 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Niccolo Allievi, Mark Sidhom, Mark Vasanth Samuel, Alexios Tzivanakis, Sanjeev Dayal, Tom Cecil, Faheez Mohamed, and Brendan Moran declare they have no conflicts of interest that may be relevant to the contents of this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}